StockNews.com started coverage on shares of Cara Therapeutics (NASDAQ:CARA – Free Report) in a report published on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.
Cara Therapeutics Stock Performance
Shares of NASDAQ:CARA opened at $0.27 on Friday. The company has a market cap of $14.71 million, a PE ratio of -0.12 and a beta of 0.70. Cara Therapeutics has a 12-month low of $0.24 and a 12-month high of $1.40. The stock has a 50 day moving average of $0.30 and a 200 day moving average of $0.45.
Cara Therapeutics (NASDAQ:CARA – Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. The company had revenue of $0.99 million for the quarter, compared to analysts’ expectations of $1.26 million. Equities research analysts predict that Cara Therapeutics will post -1.24 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Cara Therapeutics
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
Read More
- Five stocks we like better than Cara Therapeutics
- Why Are Stock Sectors Important to Successful Investing?
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- What is Short Interest? How to Use It
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- 3 Healthcare Dividend Stocks to Buy
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.